These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27885314)

  • 21. Splenectomy and surgical cytoreduction in epithelial ovarian cancer: a review.
    Hanprasertpong J; Fujiwara K
    Eur J Cancer Care (Engl); 2011 May; 20(3):287-93. PubMed ID: 20825460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer.
    Everett EN; Heuser CC; Pastore LM; Anderson WA; Rice LW; Irvin WP; Taylor PT
    Am J Obstet Gynecol; 2005 Aug; 193(2):568-74; discussion 574-6. PubMed ID: 16098898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is the role of neoadjuvant chemotherapy in the management of ovarian cancer?
    Schwartz PE
    Oncology (Williston Park); 2008 Sep; 22(10):1118-25; discussion 1130, 1132, 1134. PubMed ID: 18935925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The feasibility and morbidity of distal pancreatectomy in extensive cytoreductive surgery for advanced epithelial ovarian cancer.
    Yildirim Y; Sanci M
    Arch Gynecol Obstet; 2005 Jun; 272(1):31-4. PubMed ID: 15480722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.
    Chang SJ; Hodeib M; Chang J; Bristow RE
    Gynecol Oncol; 2013 Sep; 130(3):493-8. PubMed ID: 23747291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Up-date on cytoreductive surgery in the management of advanced ovarian cancer].
    Angioli R; Palaia I; Damiani P; Montera R; Benedetti Panici P
    Minerva Ginecol; 2006 Dec; 58(6):459-70. PubMed ID: 17108876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreaticoduodenectomy in optimal primary cytoreduction of epithelial ovarian cancer: A case report and review of the literature.
    Beissel JM; Kendrick ML; Podratz KC; Bakkum-Gamez JN
    Gynecol Oncol Rep; 2014 Dec; 10():25-7. PubMed ID: 26075997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging of Peritoneal Carcinomatosis in Advanced Ovarian Cancer: CT, MRI, Radiomic Features and Resectability Criteria.
    Miceli V; Gennarini M; Tomao F; Cupertino A; Lombardo D; Palaia I; Curti F; Riccardi S; Ninkova R; Maccioni F; Ricci P; Catalano C; Rizzo SMR; Manganaro L
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of advanced ovarian cancer in Leicester: The benefits of a paradigm shift in surgical approach.
    Barakat A; Ismail A; Chattopadhyay S
    J Obstet Gynaecol Res; 2022 Dec; 48(12):3233-3241. PubMed ID: 36151704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diaphragmatic Peritonectomy and Full-Thickness Resection in CRS/HIPEC May Allow Higher Completeness of Cytoreduction Rates with a Low Rate of Respiratory Complications.
    Craus-Miguel A; Segura-Sampedro JJ; González-Argenté X; Morales-Soriano R
    Ann Surg Oncol; 2021 Aug; 28(8):4676-4682. PubMed ID: 33409735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher Level of Fatty Acid Synthase Enzyme Predicts Lower Rate of Completing Debulking Surgery in Epithelial Ovarian Cancer.
    Winarno GNA; Hidayat Y; Soetopo S; Krisnadi SR; Tobing MDL; Rauf S
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):2859-2863. PubMed ID: 33112541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune reaction by cytoreductive prostatectomy.
    Lee GT; Srivastava A; Kwon YS; Kim IY
    Am J Clin Exp Urol; 2019; 7(2):64-79. PubMed ID: 31139701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature.
    Papadia A; Morotti M
    Arch Gynecol Obstet; 2013 Apr; 287(4):733-41. PubMed ID: 23341061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
    Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
    Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of aggressive surgical cytoreduction in advanced ovarian cancer.
    Chang SJ; Bristow RE; Chi DS; Cliby WA
    J Gynecol Oncol; 2015 Oct; 26(4):336-42. PubMed ID: 26197773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytoreductive surgery in the management of ovarian cancer.
    Schwartz PE
    Oncology (Williston Park); 2008 Aug; 22(9):1025-33; discussion 1033-8, 1041, 1045. PubMed ID: 18777954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.
    Shashikant L; Kesterson Joshua P
    J Obstet Gynaecol India; 2009; 59(3):209-216. PubMed ID: 27885314
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.